FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

ALEMBICLTD Share Price Discussion

Alembic Ltd.
NSE: ALEMBICLTD | BSE: 506235 | ISIN: INE426A01027 | Sector: Pharmaceuticals and health care

ALEMBICLTD Rating

0/5 (0 Ratings)
ALEMBICLTD Share Price *
51.15 +0.7 (1.39%)
* (quote may be delayed)
Find answers to all your questions on live ALEMBICLTD message board: Is ALEMBICLTD buy or sell? Should I buy ALEMBICLTD shares? Why are ALEMBICLTD shares falling? Should I invest in ALEMBICLTD stock?

You can also check ALEMBICLTD share price target recommended by brokerages.

ALEMBICLTD Discussion Forum

@pritpatel • Reputation: 2,422

Alembic Pharmaceuticals (Alembic) on Tuesday (28 January) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Azithromycin tablets USP, 600 mg. The approved ANDA is therapeutically equivalent...
Read more...
Like
reply
Reply

Alembic reports Q3 FY20 results during market hours. PAT grew 38% y/y to Rs 234.2 crore. Revenue increased 18.8% y/y to Rs 1,209 crore. Margin also expanded 310bps y/y to 26.9%. The stock closed 1.5% lower.
1
reply
Reply

Alembic Pharmaceuticals received tentative approval from the U.S. FDA for its abbreviated new drug application (ANDA) Empagliflozin Tablets, 10 mg and 25 mg. The stock was up 0.7%.
Like
reply
Reply
@stocktrendr • Reputation: 319

Alembic Pharma gets US FDA nod for muscle relaxant drug Tizanidine Hydrochloride
Like
reply
Reply

BRIEF-India's Alembic Receives USFDA Approvals For Deferasirox Tablets - Reuters
22-Nov-2019 12:48:46 PM
Nov 22 (Reuters) - Alembic Pharmaceuticals Ltd ALEM.NS:
RECEIVES USFDA APPROVALS
RECEIVES FINAL USFDA APPROVALS FOR DEFERASIROX TABLETS 90, 360 MG AND DEFERASIROX TABLETS FOR ...
Read more...
2
reply
Reply

Alembic Receives USFDA Approvals For Deferasirox Tablets
Like
reply
Reply
@bcatchs • Reputation: 603

ALEMBICLTD - chart - 426479
Alembic Pharma Witnessing Good Delivery Volumes. Monthly Chart Bullish Flag Breakout.
#nifty #banknifty #trading #equityderivatives #nism #StockMarket
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
  • ALEMBICLTD - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,084.98
    Enterprise Value1,082.99
    Price to Earnings34.72
    Price to Book Value2.6
    Return on Capital Employed0.12
    Return on Equity0.12
    Face Value2
    Dividend YieldNA
  • ALEMBICLTD Share Price - Technicals

    keyboard_arrow_down
    ALEMBICLTD - 52 Week High₹64.9
    ALEMBICLTD - 52 Week Low₹39.2
  • ALEMBICLTD Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 1450.852.550.5551
    Feb 1352.353.450.1550.45
    Feb 1254.254.252.2552.3
    Feb 1153.8555.153.553.65
    Feb 1053.355453.253.5
  • ALEMBICLTD Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹55.47
    30 Day Moving Average₹55.73
    50 Day Moving Average₹55.45
    100 Day Moving Average₹52.97
    200 Day Moving Average₹48.2
  • ALEMBICLTD - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue125144.26-0.13
    Operating Profit110.9111.09
    Profit Before Tax4426.630.65
    Net Income4127.490.49
  • ALEMBICLTD - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds4183460.21
    Total Liabilities58181-0.68
    Total Assets476528-0.1
  • ALEMBICLTD - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2351.63-0.55
    Cash from Investing Activity-22-46.69-0.53
    Cash from Financing Activity-2-4.96-0.6
    Net Cash Flow-1-0.0249
  • ALEMBICLTD - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.120.07
    Return on Capital Employed0.120.07
  • ALEMBICLTD - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.13
    3 Year CAGR Growth in Operating Profit0.11
    3 Year CAGR Growth in EBIDTA0.52
    3 Year CAGR Growth in Net Income0.7
    3 Yr CAGR Growth - Diluted EPS0.71
  • ALEMBICLTD - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.3
    5 Year CAGR Growth in Operating Profit-0.3
    5 Year CAGR Growth in EBIDTA0.77
    5 Year CAGR Growth in Net Income2.57
    3 Yr CAGR Growth - Diluted EPS0.79
  • ALEMBICLTD - Recent News

    keyboard_arrow_down
    NewsBot
    May 23 10:53 PM
    NewsBot
    Feb 12 11:57 PM
  • ALEMBICLTD - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.